Elagolix sodium
45-16 Ramsey Road Shirley, NY 11967, USA, New York, New York, 11967
About us
Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma. Elagolix was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued.
https://www.bocsci.com/elagolix-sodium-cas-832720-36-2-item-354739.html